Literature DB >> 24501537

Testing Overall and Subpopulation Treatment Effects with Measurement Errors.

Yanyuan Ma1, Guosheng Yin2.   

Abstract

There is a growing interest in the discovery of important predictors from many potential biomarkers for therapeutic use. In particular, a biomarker has predictive value for treatment if the treatment is only effective for patients whose biomarker values exceed a certain threshold. However, biomarker expressions are often subject to measurement errors, which may blur the biomarker's predictive capability in patient classification and, as a consequence, may lead to inappropriate treatment decisions. By taking into account the measurement errors, we propose a new testing procedure for the overall and subpopulation treatment effects in the multiple testing framework. The proposed method bypasses the permutation or other resampling procedures that become computationally infeasible in the presence of measurement errors. We conduct simulation studies to examine the performance of the proposed method, and illustrate it with a data example.

Entities:  

Keywords:  Biomarker study; clinical trial; measurement error; multiple testing; predictive marker; subgroup analysis; treatment effect

Year:  2013        PMID: 24501537      PMCID: PMC3909997          DOI: 10.5705/ss.2012.049

Source DB:  PubMed          Journal:  Stat Sin        ISSN: 1017-0405            Impact factor:   1.261


  6 in total

1.  Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.

Authors:  Boris Freidlin; Richard Simon
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

2.  Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

Authors:  Wenyu Jiang; Boris Freidlin; Richard Simon
Journal:  J Natl Cancer Inst       Date:  2007-06-27       Impact factor: 13.506

3.  Optimising the design of phase II oncology trials: the importance of randomisation.

Authors:  Mark J Ratain; Daniel J Sargent
Journal:  Eur J Cancer       Date:  2008-12-06       Impact factor: 9.162

Review 4.  Clinical trial designs for predictive marker validation in cancer treatment trials.

Authors:  Daniel J Sargent; Barbara A Conley; Carmen Allegra; Laurence Collette
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

Review 5.  Clinical trial designs for cytostatic agents: are new approaches needed?

Authors:  E L Korn; S G Arbuck; J M Pluda; R Simon; R S Kaplan; M C Christian
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

6.  The cross-validated adaptive signature design.

Authors:  Boris Freidlin; Wenyu Jiang; Richard Simon
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.